These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12150482)

  • 1. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
    Teleman MD; Chee CB; Earnest A; Wang YT
    Int J Tuberc Lung Dis; 2002 Aug; 6(8):699-705. PubMed ID: 12150482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
    Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
    Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.
    Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO
    Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
    Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
    J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
    Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
    Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia.
    Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M
    Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hepatotoxicity among patients treated with antituberculous medication.
    Cusack RP; Chawke L; O'Brien DJ; O'Connor B; O'Connor TM
    QJM; 2017 Apr; 110(4):219-225. PubMed ID: 27667826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre.
    Shu CC; Lee CH; Lee MC; Wang JY; Yu CJ; Lee LN
    Int J Tuberc Lung Dis; 2013 Jul; 17(7):934-9. PubMed ID: 23743313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome.
    Keshavjee S; Gelmanova IY; Shin SS; Mishustin SP; Andreev YG; Atwood S; Furin JJ; Miller A
    Int J Tuberc Lung Dis; 2012 May; 16(5):596-603. PubMed ID: 22410436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.
    Baghaei P; Tabarsi P; Chitsaz E; Saleh M; Marjani M; Shemirani S; Pooramiri MV; Kazempour M; Farnia P; Fahimi F; Mansouri D; Masjedi M
    Am J Ther; 2010; 17(1):17-22. PubMed ID: 19535968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
    Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
    Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment.
    Pukenyte E; Lescure FX; Rey D; Rabaud C; Hoen B; Chavanet P; Laiskonis AP; Schmit JL; May T; Mouton Y; Yazdanpanah Y
    Int J Tuberc Lung Dis; 2007 Jan; 11(1):78-84. PubMed ID: 17217134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
    Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
    Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
    Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.